MediGene and DKFZ present data from the AAVLP vaccine program at the International Papillomavirus Conference

Martinsried/Munich, September 20, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard) announces that preclinical data from its AAVLP vaccine technology will be presented today at the 27th International Papillomavirus Conference in Berlin. These data were generated in cooperation with the German Cancer Research Center (DKFZ). The oral presentation titled "Development of AAVLP (HPV16/31L2) particles as broadly protective vaccine candidates"[1] (OP-32.01) will take place today, September 20, 2011, at 6:45 pm in the Poster Area South of the International Congress Center in Berlin.

The presented data show that particles derived from MediGene's AAVLP vaccine technology, which comprise peptides from human papilloma virus (HVP) serotypes 16 and 31, induce neutralizing antibodies against a broad range of HPV serotypes in mice-vaccination studies. The in vivo studies provide evidence for the potential of the technology for the development of a prophylactic vaccine against infections of cancer-inducing HPV serotypes.

MediGene holds an extensive IP portfolio regarding the AAVLP technology, and is currently conducting research into the application of AAVLP technology for the treatment of cancer and viral infections. MediGene is also examining the possibility of using AAV libraries for the systematic identification of suitable vaccine candidates. The key benefit of this technology may be the possibility of transferring the efficacy of existing therapeutic antibodies directly into a vaccine.


MediGene' s AAVLP-based vaccine candidates have shown an excellent safety profile in preclinical studies thus far, and may therefore constitute not only an interesting alternative to conventional vaccines, but also significantly widen the range of applications for vaccines against cancer and other diseases.

This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the forward-looking statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene® is a registered trademarks of MediGene AG. These trademarks may be owned or licensed in select locations only.


- ends -


MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. MediGene is the first German biotech company to have revenues from marketed products. It has various drug candidates in clinical development and possesses innovative platform technologies. MediGene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases.

About AAVLP: In its AAVLP program, which is currently at the preclinical stage, MediGene is investigating the use of adeno-associated viruses (AAV) as a vaccine. The adeno-associated virus is non-pathogenic, i.e. it does not cause disease. The virus protein shell, the capsid, is suited for the production of so-called virus-like particles (VLP), which can be used as a basis for novel vaccines. By inserting short antigenic peptides (B-cell epitopes) into the AAV capsid, a highly specific antibody reaction against selected target molecules can be induced in the body. These antibodies can protect the body (i.e. have a prophylactic effect) or act as a therapy against existing diseases.

About HPV: The term "human papillomaviruses" describes a family of viruses that is capable of infecting the epithelium of the skin or different mucous membranes, causing tumor-like growth. The viruses are typically transmitted through sexual contact. Depending on the HPV type, the consequences of an infection vary in their severity. Some particularly aggressive types of HPV are capable of causing malignant changes, e.g. cervical cancer in women.

Contact MediGene AG
Julia Hofmann, Kerstin Langlotz
Investor & Public Relations
Tel.: +49 - 89 - 85 65 - 33 01
Fax: +49 - 89 - 85 65 - 29 20

[1] K. Nieto, S. Sedlmeier, P. Sehr, M. Ritter, M. Weghofer, M. Hörer, U. Michaelis, M. Müller, L. Gissmann, J. Kleinschmidt